I am currently Professor of Public Heath in the Department of Public Health and Primary Care at Imperial College London as well as Honorary Consultant Cardiologist at the Imperial College NHS Trust. I received my medical education (MB ChB, 1991) at the University of Birmingham Medical School, my MD (2004) at the University of Sheffield, a postdoctoral fellowship at Harvard Medical School and finally an MPhil in epidemiology (2007) from the University of Cambridge.
My research interests have focused on the prevention of cardiovascular disease with a special interest in lipids and diabetes. I have investigated the early benefits of statin therapy, the advantages of more/less intensive glycaemic control, and the risks/benefits of aspirin therapy. These have influenced AHA/ACC and ESC guidelines. My work on statins and diabetes risk led to a global label change for statins by the FDA and EMEA. I continue to investigate the role of lipids, lipoproteins, diabetes, inflammation and thrombosis and coronary events. I have received research grants including from the British Heart Foundation, the Wellcome Trust, Pfizer, Amgen, Sanofi, MSD, and the European Atherosclerosis Society (EAS). Currently I lead the EAS Familial Hypercholesterolaemia (FH) Studies collaboration which is the first global registry for FH and now includes approximately sixty countries, and am the Senior PI for the TOGETHER study looking at cardiometabolic risk in the vascular health checks in 250,000 people in London.
I am a Fellow of the American College of Cardiology, the European Society of Cardiology, the American Heart Association and the Royal College of Physicians, I am also a member of the British Cardiovascular Society and European Atherosclerosis Society. I have been the national lead investigator and have served on the steering and executive committees for several major medical trials. I am currently involved in eight trials including PI of ORION 1 and BETONMACE.
I have published over 170 research articles in numerous journals including the NEJM, Lancet, JAMA, Archives of Internal Medicine, Circulation, the Journal of the American College of Cardiology, and the European Heart Journal, which have been cited over 26,000 times.
et al., 2019, Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial., Lancet Diabetes Endocrinol
et al., 2019, Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults with heterozygous familial hypercholesterolemia, Atherosclerosis, Vol:286, ISSN:0021-9150, Pages:40-45
et al., 2019, Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials, Atherosclerosis, ISSN:0021-9150
et al., 2019, Efficacy and safety of alirocumab 300 mg every 4 weeks in individuals with type 2 diabetes on maximally tolerated statin, Journal of Clinical Endocrinology and Metabolism, ISSN:0021-972X
et al., 2019, The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: Conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation, Cardiovascular Diabetology, Vol:18, ISSN:1475-2840